Furthermore, Danirixin (GSK1325756), a selective CXCR2 antagonist, has been found to alleviate the symptoms of patients with chronic obstructive pulmonary disease (COPD) by inhibiting the formation of NETs (NCT03250689) (187). This evidence concerns the gene CXCR2 and chronic obstructive pulmonary disease.